Grifols, ES0171996087

JPMorgan cuts Grifols target from USD 10.00 to USD 9.00 for Grifols stock

Published on 10/27/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 2.60 percent to EUR 3.57 billion. Grifols stock costs EUR 10.59 on October 27, 2026 with EUR 227 million profit.

Analyst change and operating growth

JPMorgan lowered its Grifols target from USD 10.00 to USD 9.00 on October 26, 2026.
First-half revenue reached EUR 3.57 billion after 2.60 percent growth in 2026.
Grifols stock trades at EUR 10.59 at 9:48 a.m. CET at Lang & Schwarz on October 27, 2026.

Grifols, ES0171996087, Illustration mit AI erstellt.

Grifols (ES0171996087) stock was trading at EUR 10.59 at Lang & Schwarz on October 27, 2026 at 9:48 a.m. CET. JPMorgan cut its price target from USD 10.00 to USD 9.00 and kept a Neutral rating on October 26, 2026, according to Markets Insider.

JPMorgan lowers the target

The target reduction gives investors a fresh counterweight to Grifols' improving first-half operating figures. JPMorgan's new USD 9.00 target is USD 1.00 below its previous USD 10.00 target, a 10.00 percent reduction, while the Neutral rating stayed unchanged.

Three dated company milestones

Grifols reported EUR 1.70 billion of first-quarter revenue, up 3.30 percent at constant currency, on May 7, 2026. The company then reported first-half revenue of EUR 3.57 billion, up 2.60 percent at constant currency, and net profit of EUR 227.00 million, up 28.70 percent year over year, on July 28, 2026, according to Grifols. JPMorgan's October 26, 2026 target cut is the latest dated event.

What does the target cut change?

The lower target highlights valuation pressure even as the latest reported period showed stronger earnings. In the second quarter, adjusted EBITDA reached EUR 472.00 million with a 25.20 percent margin, while first-half adjusted EBITDA reached EUR 854.00 million with a 23.90 percent margin, according to Yahoo Finance. The contrast is clear: profit growth improved, but the latest analyst action became more cautious.

Next reporting dates

Grifols is scheduled to hold an earnings call on November 3, 2026 and publish third-quarter results on November 10, 2026, according to Gekko. Those dates will provide the next test of revenue growth, margins and cash generation.

Stock price and business context

Grifols develops plasma-derived therapies and diagnostics, with Biopharma identified as the main growth engine in the first half. The company said Biopharma revenue grew 5.40 percent at constant currency during that period, adding an operating counterpoint to the lower JPMorgan target.

Grifols stock was trading at EUR 10.59 at Lang & Schwarz on October 27, 2026 at 9:48 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.